AIM Biotech to Present at Biotech Showcase(TM) 2021; To Highlight Expansion of its Organ-on-a-Chip Business
AIM Biotech is participating in Biotech Showcase 2021, where CEO Jim McGorry will share the Company's plan to commercialize its organ-on-a-chip product line and contract research services. Registered attendees may access recorded company presentations prior to the event, schedule direct meetings and engage in Q&A with management.
To view the full announcement, including downloadable images, bios, and more, click here.
- CEO Jim McGorry will share the company's plan to expand its organ-on-a-chip business.
- The company sells its chips directly to researchers and as a service to drug discovery organizations.
- AIM's organ-on-a-chip helps researchers generate more predictive human data data for drug discovery and development.
Click image above to view full announcement.
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 13th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT AIM BIOTECH
AIM Biotech's platform and world-class lab services let drug researchers get more relevant, human-focused data at every stage of development. That means more informed decisions and less wasted time. Streamline your workflow. Rethink how you look at life sciences. It's time to add the human element.
Media & Investors
Source: AIM Biotech